<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">558</article-id><article-id pub-id-type="doi">10.17650/2782-3687-2022-14-1-48-54</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REAL CLINICAL CASES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Oncogenic osteomalacia/phosphaturic mesenchymal tumor: clinical case and literature review</article-title><trans-title-group xml:lang="ru"><trans-title>Онкогенная остеомаляция/фосфатурическая мезенхимальная опухоль: клиническое наблюдение и обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7592-4249</contrib-id><name-alternatives><name xml:lang="en"><surname>Bulycheva</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Булычева</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Irina Vladislavovna Bulycheva</p><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>Ирина Владиславовна Булычева</p><p>115478 Москва, Каширское шоссе, 24</p></bio><email>irena@boulytcheva.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2726-8758</contrib-id><name-alternatives><name xml:lang="en"><surname>Rodionova</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Родионова</surname><given-names>С. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>10 Priorov St., Moscow 127299</p></bio><bio xml:lang="ru"><p>127299 Москва, ул. Приорова, 10</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8280-8163</contrib-id><name-alternatives><name xml:lang="en"><surname>Karpenko</surname><given-names>V. Yu.</given-names></name><name xml:lang="ru"><surname>Карпенко</surname><given-names>В. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>10 Priorov St., Moscow 127299</p></bio><bio xml:lang="ru"><p>127299 Москва, ул. Приорова, 10</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4216-8800</contrib-id><name-alternatives><name xml:lang="en"><surname>Kolondaev</surname><given-names>A. F.</given-names></name><name xml:lang="ru"><surname>Колондаев</surname><given-names>А. Ф.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>10 Priorov St., Moscow 127299</p></bio><bio xml:lang="ru"><p>127299 Москва, ул. Приорова, 10</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlova</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Козлова</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115478</p></bio><bio xml:lang="ru"><p>115478 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0039-2118</contrib-id><name-alternatives><name xml:lang="en"><surname>Buklemishev</surname><given-names>Yu. E.</given-names></name><name xml:lang="ru"><surname>Буклемишев</surname><given-names>Ю. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>10 Priorov St., Moscow 127299</p></bio><bio xml:lang="ru"><p>127299 Москва, ул. Приорова, 10</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.N. Priorov National Medical Research Center of Traumatology and Orthopedics, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ Национальный медицинский исследовательский центр травматологии и ортопедии им. Н.Н. Приорова Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-04-13" publication-format="electronic"><day>13</day><month>04</month><year>2022</year></pub-date><volume>14</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>48</fpage><lpage>54</lpage><history><date date-type="received" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-04-13"><day>13</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Bulycheva I.V., Rodionova S.S., Karpenko V.Y., Kolondaev A.F., Kozlova E.V., Buklemishev Y.E.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Булычева И.В., Родионова С.С., Карпенко В.Ю., Колондаев А.Ф., Козлова Е.В., Буклемишев Ю.Е.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Bulycheva I.V., Rodionova S.S., Karpenko V.Y., Kolondaev A.F., Kozlova E.V., Buklemishev Y.E.</copyright-holder><copyright-holder xml:lang="ru">Булычева И.В., Родионова С.С., Карпенко В.Ю., Колондаев А.Ф., Козлова Е.В., Буклемишев Ю.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/558">https://sarbon.abvpress.ru/jour/article/view/558</self-uri><abstract xml:lang="en"><p>Phosphaturic mesenchymal tumor inducing development of phosphopenic osteomalacia is manifested as deformations and multiple fractures of the bones which decreases patients’ quality of life and leads to disability. Insufficient awareness about this pathology among doctors and absence of symptoms allowing its diagnosis cause late diagnosis of the disease despite application of up-to-date high-tech diagnostic methods. The optimal treatment of phosphaturic mesenchymal tumors is radical resection. However, strong connection of the tumor with the surrounding tissues and, in many cases, absence of a capsule or sclerosis (if located in the bones) complicate surgery leading to high recurrence rate. Radical resection of phosphaturic mesenchymal tumors is especially complicated in cases of localization in complex anatomical areas of the lower limbs.</p><p>The disease is characterized by long timespan between first clinical signs, diagnosis, and start of treatment (sometimes, several years). Diagnosis confirmation and visualization of the details of phosphaturic mesenchymal tumor requires magnetic resonance imaging. This method allows to examine connection between the tumor and surrounding tissues and the presence of a capsule. Magnetic resonance imaging also allows to accurately determine the area of surgical intervention. Radical tumor resection leads to normalization of blood and urine biochemistry in the span of several weeks. Restoration of bone density and muscle function requires 3–6 months after the operation.</p></abstract><trans-abstract xml:lang="ru"><p>Фосфатурическая мезенхимальная опухоль, индуцирующая развитие фосфопенической остеомаляции, проявляется деформациями и многочисленными переломами костей скелета, что снижает качество жизни пациентов и приводит к инвалидности. Недостаточная осведомленность врачей об этой патологии и отсутствие симптомов, позволяющих ее выявить, являются причинами поздней диагностики заболевания даже при использовании современных высоко-технологичных методов обследования. Оптимальным лечением фосфатурических мезенхимальных опухолей является их радикальное иссечение. Однако тесная связь данного новообразования с окружающими тканями и во многих случаях отсутствие капсулы или склероза (при локализации в костях) усложняют выполнение операции, что объясняет высокую склонность опухоли к рецидиву. Особые трудности при радикальном удалении фосфатурических мезенхимальных опухолей возникают при их локализации в сложных анатомических областях нижних конечностей.</p><p>Характерен длительный промежуток времени между первыми клиническими проявлениями заболевания, постановкой диагноза и началом лечения (иногда он составляет несколько лет). Для уточнения диагноза и визуализации деталей фосфатурической мезенхимальной опухоли необходима магнитно-резонансная томография. Этот метод позволяет исследовать связь опухоли с прилегающими тканями, а также выявить наличие капсулы. Магнитно-резонансная терапия также помогает точно определить зону хирургического вмешательства. Радикальное удаление опухоли приводит к нормализации биохимических показателей крови и мочи в течение нескольких недель. Восстановление плотности костной ткани и мышечной функции происходит в течение 3–6 мес после операции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>oncogenic osteomalacia</kwd><kwd>osteoporosis</kwd><kwd>phosphaturic mesenchymal tumor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>онкогенная остеомаляция</kwd><kwd>остеопороз</kwd><kwd>фосфатурическая мезенхимальная опухоль</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was performed without external funding</funding-statement><funding-statement xml:lang="ru">Работа выполнена без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. McCance R.A. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age 15 years. QJMed 1947;16(1);33–47.</mixed-citation><mixed-citation xml:lang="ru">McCance R.A. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age 15 years. QJMed 1947;16(1);33–47.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Prader A., Illig R., Uehlinger R.E. et al. Rachitis infolge knochentumors [rickets caused by bone tumors]. Helv Pediatr Acta 1959;14:554–65.</mixed-citation><mixed-citation xml:lang="ru">Prader A., Illig R., Uehlinger R.E. et al. Rachitis infolge knochentumors [rickets caused by bone tumors]. Helv Pediatr Acta 1959;14:554–65.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Sundaram M., McCarthy E.F. Oncogenic osteomalacia. Skeletal radiol 2000;29(3);117–24. DOI: 10.1007/s002560050581.</mixed-citation><mixed-citation xml:lang="ru">Sundaram M., McCarthy E.F. Oncogenic osteomalacia. Skeletal radiol 2000;29(3);117–24. DOI: 10.1007/s002560050581.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Bowe A.E., Finnegan R., Jan de Beur S.M. et al. FGF-23 inhibits renal tubular phosphate transport and is a PENX substrate. Biochem Biophys res Commun 2001;284(4):977–81. DOI: 10.1006/bbrc.2001.5084.</mixed-citation><mixed-citation xml:lang="ru">Bowe A.E., Finnegan R., Jan de Beur S.M. et al. FGF-23 inhibits renal tubular phosphate transport and is a PENX substrate. Biochem Biophys res Commun 2001;284(4):977–81. DOI: 10.1006/bbrc.2001.5084.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Shimada T., Mizutani S., Muto T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98(11):6500–5. DOI: 10.1073/pnas.101545198.</mixed-citation><mixed-citation xml:lang="ru">Shimada T., Mizutani S., Muto T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98(11):6500–5. DOI: 10.1073/pnas.101545198.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nat Genet 2000;26(3):345–8. DOI: 10.1038/81664.</mixed-citation><mixed-citation xml:lang="ru">ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nat Genet 2000;26(3):345–8. DOI: 10.1038/81664.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Vigorita V.J. Orthopaedic Pathology. Lippincott Williams and Wilkins, 2008.</mixed-citation><mixed-citation xml:lang="ru">Vigorita V.J. Orthopaedic Pathology. Lippincott Williams and Wilkins, 2008.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Folpe A.L., Fanburg-Smith J.C., Billings S.D. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28(1):1–30. DOI: 10.1097/00000478-200401000-00001.</mixed-citation><mixed-citation xml:lang="ru">Folpe A.L., Fanburg-Smith J.C., Billings S.D. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004;28(1):1–30. DOI: 10.1097/00000478-200401000-00001.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Siegel H.J., Rock M.G. Occult phosphaturic mesenchimal tumor detected by Tc-99m sestamibi scan. Clin Nucl Med 2002;27:608–9.</mixed-citation><mixed-citation xml:lang="ru">Siegel H.J., Rock M.G. Occult phosphaturic mesenchimal tumor detected by Tc-99m sestamibi scan. Clin Nucl Med 2002;27:608–9.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Qui L., Heim-Hall J. Nonphosphaturic variant of phosphaturic mesenchymal tumor, mixed connective tissue type: a case report. Am J Clin Pathol 2018;149(1):S118. DOI: 10.1093/ajcp/aqx123.277.</mixed-citation><mixed-citation xml:lang="ru">Qui L., Heim-Hall J. Nonphosphaturic variant of phosphaturic mesenchymal tumor, mixed connective tissue type: a case report. Am J Clin Pathol 2018;149(1):S118. DOI: 10.1093/ajcp/aqx123.277.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Weidner N., Santa Cruz D. Phosphaturic mesenphymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 1987;59(8);1442–54. DOI: 10.1002/1097-0142(19870415)59:8&lt;1442::aid-cncr2820590810&gt;3.0.co;2-q.</mixed-citation><mixed-citation xml:lang="ru">Weidner N., Santa Cruz D. Phosphaturic mesenphymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer 1987;59(8);1442–54. DOI: 10.1002/1097-0142(19870415)59:8&lt;1442::aid-cncr2820590810&gt;3.0.co;2-q.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Asching L.C., Solomon L.M., Zeis P.M. et al. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in dermal lesions. J Pediatr 1977;91(1):56–60. DOI: 10.1016/s0022-3476(77)80444-7.</mixed-citation><mixed-citation xml:lang="ru">Asching L.C., Solomon L.M., Zeis P.M. et al. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in dermal lesions. J Pediatr 1977;91(1):56–60. DOI: 10.1016/s0022-3476(77)80444-7.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Xiao X., Sun X., Ni P. et al. Phosphaturic mesenchymal tumor and related wound problem. Medicine (Baltimore) 2018;97(40):e12507. DOI: 10.1097/MD.0000000000012507.</mixed-citation><mixed-citation xml:lang="ru">Xiao X., Sun X., Ni P. et al. Phosphaturic mesenchymal tumor and related wound problem. Medicine (Baltimore) 2018;97(40):e12507. DOI: 10.1097/MD.0000000000012507.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Folpe A.L. Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 2019;36(4):260–8. DOI: 10.1053/j.semdp.2019.07.002.</mixed-citation><mixed-citation xml:lang="ru">Folpe A.L. Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 2019;36(4):260–8. DOI: 10.1053/j.semdp.2019.07.002.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
